To include your compound in the COVID-19 Resource Center, submit it here.

CHMP expresses doubts on Puma's neratinib

Puma Biotechnology Inc. (NASDAQ:PBYI) said EMA's CHMP communicated a "negative trend vote" for its MAA for neratinib as extended adjuvant treatment of

Read the full 226 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE